Biotech: Page 29
-
Permission granted by Sionna Therapeutics
Sionna raises another $182M to challenge Vertex in cystic fibrosis
Incubated by RA Capital and backed by a wide array of investors, the startup is developing drugs that work differently than Vertex’s market-leading medicines.
By Gwendolyn Wu • March 6, 2024 -
Permission granted by Nasdaq, Inc.
Biotech IPOs heated up to start 2024. Will the surge last?
Following the sector’s best IPO start in three years, BioPharma Dive spoke with industry insiders about what they expect to see in the months ahead.
By Gwendolyn Wu , Ben Fidler • March 5, 2024 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Prostock-Studio via Getty Images
Nocion, chasing GSK, pulls in $62M for chronic cough drug
Nocion will use the cash to start a mid-stage trial testing its medicine, a potential rival to a drug GSK acquired last year in a $2 billion deal.
By Gwendolyn Wu • March 4, 2024 -
Stock via Getty Images
Bayer pays $310M to buy into BridgeBio heart drug
The deal gives the German pharma partial rights to a closely watched medicine for transthyretin amyloidosis cardiomyopathy that analysts expect to become a multibillion-dollar product.
By Ben Fidler • March 4, 2024 -
Permission granted by QIAGEN
Sponsored by QIAGENUsing knowledge graphs to drive drug discovery
How are knowledge graphs changing the path of drug discovery?
March 4, 2024 -
Permission granted by FogPharma
FogPharma pulls in $145M to support cancer drug research
The cash will be used to advance development of FOG-001, the company’s lead drug that’s now being tested in an early-stage trial for solid tumors.
By Gwendolyn Wu • March 1, 2024 -
Andrii Yalanskyi via Getty Images
Gritstone to lay off 40% of workforce after costly study delay
The restructuring comes ahead of a key study readout for Gritstone, which, like Moderna, is developing a type of personalized cancer vaccine.
By Ben Fidler • March 1, 2024 -
Courtesy of Cure Ventures
Cure Ventures backs a cell therapy startup targeting Parkinson’s
The startup, Kenai Therapeutics, has raised $82 million and will be chaired by Jeff Jonas, a new Cure partner and former CEO of Sage Therapeutics.
By Jacob Bell • Feb. 29, 2024 -
GomezDavid via Getty Images
With BlossomHill, former Turning Point execs take aim at cancer, autoimmune disease
Less than two years after Bristol Myers bought Turning Point for $4.1 billion, Jean Cui and Peter Li have built a new startup that’s brought in more than $170 million in funding.
By Ned Pagliarulo • Feb. 29, 2024 -
Permission granted by Gilead Sciences
Abingworth invests in Trodelvy development in deal with Gilead
One of the investment firm’s startups will work with Gilead to expand the cancer drug’s label under the unusual arrangement, with Abingworth receiving payment if successful.
By Kristin Jensen • Feb. 29, 2024 -
Ozankutsal via Getty Images
Women’s health company Obseva to wind down, lay off staff
The company is still attempting to “monetize” its most advanced drug, a treatment to aid pregnancy via in vitro fertilization.
By Delilah Alvarado • Feb. 28, 2024 -
Viatris pays $350M to gain two drugs from Idorsia
The deal gives Viatris access to a treatment for heart attacks as well as a drug for lupus, both of which are currently in Phase 3 testing.
By Kristin Jensen • Feb. 28, 2024 -
Courtesy of Ginkgo Bioworks
Ginkgo adds gene editing tools in buyout of Feng Zhang-founded startup
The acquisition of Proof Diagnostics, which was formed to develop a COVID-19 test, gives Ginkgo a library of novel enzymes for making genetic medicines.
By Gwendolyn Wu • Feb. 28, 2024 -
Permission granted by Lindus Health
Can a Moderna co-founder change the CRO game?
Well-known scientist and biotech entrepreneur Robert Langer is helping Lindus Health address longstanding challenges in contract drug research.
By Michael Gibney • Feb. 28, 2024 -
Elizabeth Regan/BioPharma Dive
Viking data suggest obesity drug could rival Zepbound, Wegovy
The biotech’s drug led to significant weight loss in a Phase 2 trial, causing shares to double as analysts compared results to the marks set by drugs from Eli Lilly and Novo Nordisk.
By Jonathan Gardner • Feb. 27, 2024 -
koto_feja via Getty Images
Janux shares triple on early cancer immunotherapy data
Analysts viewed results for one of Janux’s drug, a T cell engager aimed at metastatic prostate cancer, as potentially best-in-class in a field that’s crowded with competitors.
By Ned Pagliarulo • Feb. 27, 2024 -
Honglouwawa via Getty Images
Denali, fresh off study setback, gets $500M lift
The infusion from unnamed private investors will bolster the company’s balance sheet days after a Sanofi-partnered ALS drug stumbled in a clinical trial.
By Delilah Alvarado • Feb. 27, 2024 -
ismagilov via Getty Images
BioMarin preaches patience amid slow sales for hemophilia gene therapy
The company earned only $3.5 million last year from its Roctavian treatment, far below the $50 million to $150 million range it had forecast eight months ago.
By Ben Fidler • Feb. 23, 2024 -
Permission granted by Frontier Medicines
Frontier gets $80M, Galapagos’ backing to make a better KRAS drug
The startup’s Series C round will support a clinical-stage drug the company thinks could address the shortcomings of other KRAS-targeting medicines.
By Gwendolyn Wu • Feb. 22, 2024 -
Win McNamee via Getty Images
Biden administration pledges $100M toward women’s health research
The commitment is part of an initiative led by First Lady Jill Biden to change how research into diseases that mostly affect women gets funded in the U.S.
By Delilah Alvarado • Feb. 22, 2024 -
Maddie Meyer via Getty Images
Moderna pitches RSV shot, new vaccines after ‘difficult year of transition’
The biotech is counting on an experimental RSV vaccine, currently under review by the FDA, to drive sales in the future.
By Ned Pagliarulo • Feb. 22, 2024 -
Carsten Koall/Getty Images via Getty Images
Novavax agrees to pay Gavi in settlement over COVID vaccine contract
Under the deal’s terms, Novavax will pay the vaccine alliance up to $475 million over five years.
By Kristin Jensen • Feb. 22, 2024 -
FotografiaBascia via Getty Images
ORI Capital, the venture firm behind CG’s big IPO, raises new biotech fund
The $260 million fund will be used to back startups working on new drugmaking approaches like protein degraders and RNA therapies.
By Ben Fidler • Feb. 22, 2024 -
jamenpercy via Getty Images
Vir, in midst of restructuring, loses its chief medical officer
The departure of Phil Pang, who played a key role in developing Vir’s COVID-19 antibody, comes amid a broader company restructuring.
By Delilah Alvarado • Feb. 21, 2024 -
Meletios Verras via Getty Images
Bavarian Nordic terminates cancer vaccine work
The Danish company scrapped a vaccine in Phase 1 testing and will exit oncology altogether, focusing instead on infectious disease research.
By Jonathan Gardner • Feb. 21, 2024
Previous
